Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK
A. Czira (Brentford, Middlesex, United Kingdom), V. Banks (Bollington, Cheshire, United Kingdom), G. Requena (Brentford, Middlesex, United Kingdom), R. Wood (Bollington, Cheshire, United Kingdom), T. Tritton (Bollington, Cheshire, United Kingdom), E. Ha (Bollington, Cheshire, United Kingdom), R. Wild (Bollington, Cheshire, United Kingdom), C. Compton (Brentford, Middlesex, United Kingdom), A. Ismaila (Collegeville, PA, United States of America)
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Session: Inhaled treatments for COPD: real-world data
Session type: E-poster
Number: 2411
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Czira (Brentford, Middlesex, United Kingdom), V. Banks (Bollington, Cheshire, United Kingdom), G. Requena (Brentford, Middlesex, United Kingdom), R. Wood (Bollington, Cheshire, United Kingdom), T. Tritton (Bollington, Cheshire, United Kingdom), E. Ha (Bollington, Cheshire, United Kingdom), R. Wild (Bollington, Cheshire, United Kingdom), C. Compton (Brentford, Middlesex, United Kingdom), A. Ismaila (Collegeville, PA, United States of America). Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK. 2411
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: